{"database": "openregs", "table": "cfr_sections", "is_view": false, "human_description_en": "where part_number = 556 sorted by section_id", "rows": [["21:21:6.0.1.1.18.1.2.1", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "A", "Subpart A\u2014General Provisions", "", "\u00a7 556.1 Scope.", "FDA", "", "", "", "(a) The Federal Food, Drug, and Cosmetic Act requires an applicant seeking approval or conditional approval of a new animal drug to submit a proposed tolerance as part of its new animal drug application when such a tolerance is needed to assure that the proposed use of the new animal drug will be safe (see sections 512(b)(1)(H) and 571(a)(2)(A) of the Federal Food, Drug, and Cosmetic Act). FDA assigns tolerances for animal drugs used in food-producing animals as part of the application approval process. Tolerances for approved and conditionally approved new animal drugs are codified in subpart B of this part.\n\n(b) Compounds that have been found to be carcinogenic are regulated under subpart E of part 500 of this chapter."], ["21:21:6.0.1.1.18.1.2.2", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "A", "Subpart A\u2014General Provisions", "", "\u00a7 556.3 Definitions.", "FDA", "", "", "", "As used in this part:\n\nAcceptable daily intake (ADI)  means the daily intake which, during up to an entire life of a human, appears to be without adverse effects or harm to the health of the consumer. The ADI most often will be set on the basis of the drug's toxicological, microbiological, or pharmacological properties. It is usually expressed in micrograms or milligrams of the chemical per kilogram of body weight per day.\n\nAcute reference dose (ARfD)  means an estimate of the amount of residues expressed on a body weight basis that can be ingested in a period of 24 hours or less without adverse effects or harm to the health of the human consumer.\n\nEdible tissues  means muscle, liver, kidney, fat, skin with fat in natural proportions, whole eggs, whole milk, and honey.\n\nMarker residue  means the residue whose concentration is in a known relationship to the concentration of total residue in an edible tissue.\n\nmg/kg  means milligrams per kilogram.\n\nNot required,  in reference to tolerances in this part, means that at the time of approval:\n\n(1) No withdrawal period was necessary for residues of the drug to deplete to or below the concentrations considered to be safe, or an adequate withdrawal period was inherent in the proposed drug use, and there was a rapid depletion of residues, so there was no concern about residues resulting from misuse or overdosing; or\n\n(2) No withdrawal period was necessary because the drug was poorly absorbed or metabolized rapidly so as to make selection of an analyte impractical or impossible.\n\nppb  means parts per billion (equivalent to nanograms per gram (ng/g) or \u00b5g/kg).\n\nppm  means parts per million (equivalent to micrograms per gram (\u00b5g/g) or mg/kg).\n\nppt  means parts per trillion (equivalent to picograms per gram (pg/g) or nanograms per kilogram (ng/kg)).\n\nResidue  means any compound present in edible tissues that results from the use of a drug, and includes the drug, its metabolites, and any other substance formed in or on food because of the drug's use.\n\nTarget tissue  means the edible tissue selected to monitor for residues in the target animals.\n\nTolerance  means the maximum concentration of a marker residue, or other residue indicated for monitoring, that can legally remain in a specific edible tissue of a treated animal.\n\nTotal residue  means the aggregate of all compounds that results from the use of an animal drug, including the drug, its metabolites, and any other substances formed in or on food because of such drug use.\n\n\u00b5g/kg  means microgram per kilogram.\n\nZero,  in reference to tolerances in this part, means any residues detected in the edible tissue renders it unsafe."], ["21:21:6.0.1.1.18.1.2.3", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "A", "Subpart A\u2014General Provisions", "", "\u00a7 556.5 General considerations.", "FDA", "", "", "", "(a) The tolerances listed in subpart B of this part pertain only to the species and production classes of the animal for which the drug use has been approved or conditionally approved. Approved and conditionally approved conditions of use in parts 516, 520, 522, 524, 526, 529, and 558 of this chapter, including the species and production classes of animals, are referenced in each tolerance section in subpart B of this part.\n\n(b) All tolerances refer to the concentrations of a marker residue, or other residue indicated for monitoring, permitted in uncooked tissues.\n\n(c) After a tolerance is listed, the finding that the concentration of the marker residue in the target tissue from a tested animal is at or below the tolerance indicates that all edible tissues (excluding milk and eggs unless otherwise indicated) from that tested animal are safe for human consumption. If a listed tolerance is not expressly linked to a target tissue, then the tolerance is specific only for the named edible tissue and inferences cannot be made about the safety of the other edible tissues from the tested animal.\n\n(d) FDA requires that a drug sponsor submit a practicable method as part of their new animal drug application. FDA uses the practicable method to determine the quantity of the drug residues that can safely remain in edible tissues ( i.e.,  the tolerance), the withdrawal period, and any other use restrictions necessary to ensure that the proposed use of the drug will be safe."], ["21:21:6.0.1.1.18.2.2.1", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.34 Albendazole.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of albendazole is 5 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for albendazole 2-aminosulfone (marker residue) are:\n\n(1)  Cattle.  (i) Liver (target tissue): 0.2 ppm.\n\n(ii) Muscle: 0.05 ppm.\n\n(2)  Sheep.  (i) Liver (target tissue): 0.25 ppm.\n\n(ii) Muscle: 0.05 ppm.\n\n(3)  Goat.  (i) Liver (target tissue): 0.25 ppm.\n\n(ii) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.38a and 520.38b of this chapter."], ["21:21:6.0.1.1.18.2.2.10", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.75 Bambermycins.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerances for bambermycins are:\n\n(1)  Cattle.  Edible tissues (excluding milk): Not required.\n\n(2)  Chickens and turkeys.  Edible tissues (excluding eggs): Not required.\n\n(3)  Swine.  Edible tissues: Not required.\n\n(c)  Related conditions of use.  See \u00a7 558.95 of this chapter."], ["21:21:6.0.1.1.18.2.2.100", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.750 Virginiamycin.", "FDA", "", "", "[84 FR 32993, July 11, 2019, as amended at 85 FR 18121, Apr. 1, 2020]", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of virginiamycin is 250 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for virginiamycin are:\n\n(1)  Cattle.  Edible tissues (excluding milk): Not required.\n\n(2)  Chickens.  Edible tissues (excluding eggs): Not required.\n\n(3)  Swine.  (i) Kidney, skin, and fat: 0.4 ppm.\n\n(ii) Liver: 0.3 ppm.\n\n(iii) Muscle: 0.1 ppm.\n\n(c)  Related conditions of use.  See \u00a7 558.635 of this chapter."], ["21:21:6.0.1.1.18.2.2.101", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.760 Zeranol.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of zeranol is 1.25 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for zeranol are:\n\n(1)  Cattle.  Edible tissues (excluding milk): Not required.\n\n(2)  Sheep.  Edible tissues (excluding milk): 20 ppb.\n\n(c)  Related conditions of use.  See \u00a7 522.2680 of this chapter."], ["21:21:6.0.1.1.18.2.2.102", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.765 Zilpaterol.", "FDA", "", "", "[84 FR 32993, July 11, 2019, as amended at 85 FR 18121, Apr. 1, 2020]", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of zilpaterol is 0.083 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerance for zilpaterol freebase (marker residue) is:\n\n(1)  Cattle.  (i) Liver (target tissue): 12 ppb.\n\n(ii) Muscle: 10 ppb.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 558.665 of this chapter."], ["21:21:6.0.1.1.18.2.2.103", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.770 Zoalene.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerances for zoalene and its metabolite 3-amino-5-nitro- o -toluamide are:\n\n(1)  Chickens.  (i) Liver and kidney: 6 ppm.\n\n(ii) Muscle: 3 ppm.\n\n(iii) Fat: 2 ppm.\n\n(2)  Turkeys.  Liver and muscle: 3 ppm.\n\n(c)  Related conditions of use.  See \u00a7 558.680 of this chapter."], ["21:21:6.0.1.1.18.2.2.11", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.100 Carbadox.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerance for quinoxaline-2-carboxylic acid (marker residue) is:\n\n(1)  Swine.  Liver (target tissue): 30 ppb.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 558.115 of this chapter."], ["21:21:6.0.1.1.18.2.2.12", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.110 Carbomycin.", "FDA", "", "", "[84 FR 32993, July 11, 2019, as amended at 88 FR 55567, Aug. 16, 2023]", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerance for carbomycin is:\n\n(1)  Chickens.  Edible tissues (excluding eggs): Zero.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 520.1664 of this chapter."], ["21:21:6.0.1.1.18.2.2.13", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.113 Ceftiofur.", "FDA", "", "", "", "(a)  Acceptable daily intake and acute reference dose \u2014(1)  Acceptable daily intake (ADI).  The ADI for total residue of ceftiofur is 30 \u00b5g/kg of body weight per day.\n\n(2)  Acute reference dose (ARfD).  The ARfD for total residue of ceftiofur is 0.830 mg/kg of body weight.\n\n(b)  Tolerances.  The tolerances for desfuroylceftiofur (marker residue) are:\n\n(1)  Cattle.  (i) Kidney (target tissue): 0.4 ppm.\n\n(ii) Liver: 2 ppm.\n\n(iii) Muscle: 1 ppm.\n\n(iv) Milk: 0.1 ppm.\n\n(2)  Chickens and turkeys.  Edible tissues (excluding eggs): Not required.\n\n(3)  Goats.  (i) Kidney (target tissue): 8 ppm.\n\n(ii) Liver: 2 ppm.\n\n(iii) Muscle: 1 ppm.\n\n(iv) Milk: 0.1 ppm.\n\n(4)  Sheep.  Edible tissues (excluding milk): Not required.\n\n(5)  Swine.  (i) Kidney (target tissue): 0.25 ppm.\n\n(ii) Liver: 3 ppm.\n\n(iii) Muscle: 2 ppm.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 522.313a, 522.313b, 522.313c, and 526.313 of this chapter."], ["21:21:6.0.1.1.18.2.2.14", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.115 Cephapirin.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerances for cephapirin are:\n\n(1)  Cattle.  (i) Edible tissues (excluding milk): 0.1 ppm.\n\n(ii) Milk: 0.02 ppm.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7\u00a7 526.363 and 526.365 of this chapter."], ["21:21:6.0.1.1.18.2.2.15", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.118 Chloramine-T.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of chloramine-T is 5 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerance for  para -toluenesulfonamide (marker residue) is:\n\n(1)  Fish.  Muscle/skin (target tissue): 0.9 ppm.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 529.382 of this chapter."], ["21:21:6.0.1.1.18.2.2.16", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.120 Chlorhexidine.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerance for chlorhexidine is:\n\n(1)  Cattle.  Edible tissues (excluding milk): Zero.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 529.400 of this chapter."], ["21:21:6.0.1.1.18.2.2.17", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.150 Chlortetracycline.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of tetracyclines including chlortetracycline, oxytetracycline, and tetracycline is 25 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for the sum of tetracycline residues are:\n\n(1)  Cattle.  (i) Liver: 6 ppm.\n\n(ii) Kidney and fat: 12 ppm.\n\n(iii) Muscle: 2 ppm.\n\n(2)  Chickens, turkeys, and ducks.  (i) Liver: 6 ppm.\n\n(ii) Kidney and fat: 12 ppm.\n\n(iii) Muscle: 2 ppm.\n\n(iv) Eggs: 0.4 ppm for chlortetracycline only.\n\n(3)  Sheep.  (i) Liver: 6 ppm.\n\n(ii) Kidney and fat: 12 ppm.\n\n(iii) Muscle: 2 ppm.\n\n(4)  Swine.  (i) Liver: 6 ppm.\n\n(ii) Kidney and fat: 12 ppm.\n\n(iii) Muscle: 2 ppm.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.441, 520.443, 520.445, 558.128, and 558.140 of this chapter."], ["21:21:6.0.1.1.18.2.2.18", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.160 Clopidol.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerances for clopidol are:\n\n(1)  Chickens and turkeys.  (i) Liver and kidney: 15 ppm.\n\n(ii) Muscle: 5 ppm.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 558.175 of this chapter."], ["21:21:6.0.1.1.18.2.2.19", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.163 Clorsulon.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of clorsulon is 8 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for clorsulon (marker residue) are:\n\n(1)  Cattle.  (i) Kidney (target tissue): 1.0 ppm.\n\n(ii) Muscle: 0.1 ppm.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.462 and 522.1193 of this chapter."], ["21:21:6.0.1.1.18.2.2.2", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.36 Altrenogest.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of altrenogest is 0.04 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for altrenogest (marker residue) are:\n\n(1)  Swine.  (i) Liver (target tissue): 4 ppb.\n\n(ii) Muscle: 1 ppb.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 520.48 of this chapter."], ["21:21:6.0.1.1.18.2.2.20", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.165 Cloxacillin.", "FDA", "", "", "[84 FR 32993, July 11, 2019, as amended at 85 FR 18121, Apr. 1, 2020; 86 FR 13188, Mar. 8, 2021]", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerance for cloxacillin is:\n\n(1)  Cattle.  Edible tissues: 0.01 ppm.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7\u00a7 526.464 and 526.465 of this chapter."], ["21:21:6.0.1.1.18.2.2.21", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.167 Colistimethate.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerance for colistimethate is:\n\n(1)  Chickens.  Edible tissues (excluding eggs): Not required.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 522.468 of this chapter."], ["21:21:6.0.1.1.18.2.2.22", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.168 Coumaphos.", "FDA", "", "", "[86 FR 14821, Mar. 19, 2021]", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerances for coumaphos (measured as coumaphos and its oxygen analog, O,O-diethyl O-3- chloro-4-methyl-2-oxo-2 H-1- benzopyran-7-yl phosphate) are:\n\n(1)  Chickens.  (i) Edible tissues (excluding eggs): 1 ppm.\n\n(ii) Eggs: 0.1 ppm.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 558.185 of this chapter."], ["21:21:6.0.1.1.18.2.2.23", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.169 Danofloxacin.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of danofloxacin is 2.4 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for danofloxacin (marker residue) are:\n\n(1)  Cattle.  (i) Liver (target tissue): 0.2 ppm.\n\n(ii) Muscle: 0.2 ppm.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 522.522 of this chapter."], ["21:21:6.0.1.1.18.2.2.24", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.170 Decoquinate.", "FDA", "", "", "[84 FR 32993, July 11, 2019, as amended at 86 FR 13188, Mar. 8, 2021]", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of decoquinate is 75 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for decoquinate are:\n\n(1)  Cattle.  (i) Muscle: 1 ppm.\n\n(ii) Other edible tissues (excluding milk): 2 ppm.\n\n(2)  Chickens.  (i) Muscle: 1 ppm.\n\n(ii) Other edible tissues (excluding eggs): 2 ppm.\n\n(3)  Goats.  (i) Muscle: 1 ppm.\n\n(ii) Other edible tissues (excluding milk): 2 ppm.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.534 and 558.195 of this chapter."], ["21:21:6.0.1.1.18.2.2.25", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.180 Dichlorvos.", "FDA", "", "", "[84 FR 32993, July 11, 2019, as amended at 86 FR 13188, Mar. 8, 2021]", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerance for dichlorvos is:\n\n(1)  Swine.  Edible tissues: 0.1 ppm.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.596 and 558.198 of this chapter."], ["21:21:6.0.1.1.18.2.2.26", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.185 Diclazuril.", "FDA", "", "", "[84 FR 32993, July 11, 2019, as amended at 86 FR 13188, Mar. 8, 2021]", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of diclazuril is 25 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for diclazuril are:\n\n(1)  Chickens and turkeys.  (i) Liver: 3 ppm.\n\n(ii) Muscle: 0.5 ppm.\n\n(iii) Skin/fat: 1 ppm.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 558.205 of this chapter."], ["21:21:6.0.1.1.18.2.2.27", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.200 Dihydrostreptomycin.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerances for dihydrostreptomycin are:\n\n(1)  Cattle.  (i) Kidney: 2.0 ppm.\n\n(ii) Other edible tissues (excluding milk): 0.5 ppm.\n\n(iii) Milk: 0.125 ppm.\n\n(2)  Swine.  (i) Kidney: 2.0 ppm.\n\n(ii) Other edible tissues: 0.5 ppm.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 522.650, 526.1696b, and 526.1696c of this chapter."], ["21:21:6.0.1.1.18.2.2.28", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.222 Doramectin.", "FDA", "", "", "[84 FR 32993, July 11, 2019, as amended at 88 FR 16549, Mar. 20, 2023]", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of doramectin is 0.75 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for doramectin (marker residue) are:\n\n(1)  Cattle.  (i) Liver (target tissue): 300 ppb.\n\n(ii) Muscle: 30 ppb.\n\n(2)  Swine.  Liver (target tissue): 160 ppb.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 522.770, 522.772, and 524.770 of this chapter."], ["21:21:6.0.1.1.18.2.2.29", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.224 Efrotomycin.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of efrotomycin is 10 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerance for efrotomycin is:\n\n(1)  Swine.  Edible tissues: Not required.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 558.235 of this chapter."], ["21:21:6.0.1.1.18.2.2.3", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.38 Amoxicillin.", "FDA", "", "", "[84 FR 32993, July 11, 2019, as amended at 86 FR 13188, Mar. 8, 2021]", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerance for amoxicillin is:\n\n(1)  Cattle.  Edible tissues: 0.01 ppm.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.88d, 520.88e, 522.88, and 526.88 of this chapter."], ["21:21:6.0.1.1.18.2.2.30", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.226 Enrofloxacin.", "FDA", "", "", "[84 FR 32993, July 11, 2019, as amended at 86 FR 13188, Mar. 8, 2021]", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of enrofloxacin is 3 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for enrofloxacin are:\n\n(1)  Cattle.  Liver (target tissue): 0.1 ppm desethylene ciprofloxacin (marker residue).\n\n(2)  Swine.  Liver (target tissue): 0.5 ppm enrofloxacin (marker residue).\n\n(c)  Related conditions of use.  See \u00a7\u00a7 516.812 and 522.812 of this chapter."], ["21:21:6.0.1.1.18.2.2.31", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.227 Eprinomectin.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of eprinomectin is 10 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for eprinomectin B 1a  (marker residue) are:\n\n(1)  Cattle.  (i) Liver (target tissue): 1.5 ppm.\n\n(ii) Muscle: 100 ppb.\n\n(iii) Milk: 12 ppb.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7\u00a7 522.814 and 524.814 of this chapter."], ["21:21:6.0.1.1.18.2.2.32", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.230 Erythromycin.", "FDA", "", "", "[84 FR 32993, July 11, 2019, as amended at 85 FR 18121, Apr. 1, 2020]", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerances for erythromycin are:\n\n(1)  Cattle.  (i) Edible tissues (excluding milk): 0.1 ppm.\n\n(ii) Milk: Zero.\n\n(2)  Chickens and turkeys.  (i) Edible tissues (excluding eggs): 0.125 ppm.\n\n(ii) Eggs: 0.025 ppm.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.823, 522.820, 526.820, and 558.248 of this chapter."], ["21:21:6.0.1.1.18.2.2.33", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.240 Estradiol and related esters.", "FDA", "", "", "[84 FR 32993, July 11, 2019, as amended at 87 FR 17947, Mar. 29, 2022]", "(a) [Reserved]\n\n(b)  Residues.  Residues of estradiol are not permitted in excess of the following increments above the concentrations of estradiol naturally present in untreated animals:\n\n(1)  Cattle.  (i) Muscle: 0.2 ppb.\n\n(ii) Liver: 0.6 ppb.\n\n(iii) Kidney: 1.2 ppb.\n\n(iv) Fat: 1.2 ppb.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7\u00a7 522.840, 522.850, 522.1940, 522.2343, 522.2477, and 522.2478 of this chapter."], ["21:21:6.0.1.1.18.2.2.34", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.260 Ethopabate.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerances for ethopabate, measured as metaphenetidine, are:\n\n(1)  Chickens.  (i) Liver: 1.5 ppm.\n\n(ii) Kidney: 1.5 ppm.\n\n(iii) Muscle: 0.5 ppm.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 558.58 of this chapter."], ["21:21:6.0.1.1.18.2.2.35", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.273 Famphur.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerance for famphur including its oxygen analog is:\n\n(1)  Cattle.  Edible tissues (excluding milk): 0.1 ppm.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.1242g, 524.900, and 558.254 of this chapter."], ["21:21:6.0.1.1.18.2.2.36", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.275 Fenbendazole.", "FDA", "", "", "[84 FR 32993, July 11, 2019, as amended at 86 FR 57998, Oct. 20, 2021; 86 FR 61686, Nov. 8, 2021; 89 FR 85428, Oct. 28, 2024]", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of fenbendazole is 40 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for fenbendazole are:\n\n(1)  Cattle.  (i) Liver (target tissue): 0.8 ppm fenbendazole (marker residue).\n\n(ii) Milk: 0.22 ppm fenbendazole sulfoxide (marker residue).\n\n(2)  Chickens.  (i) Liver (target tissue): 5.2 ppm fenbendazole sulfone (marker residue).\n\n(ii) Eggs: 1.8 ppm fenbendazole sulfone (marker residue).\n\n(3)  Goats.  (i) Liver (target tissue): 0.8 ppm fenbendazole (marker residue).\n\n(ii) [Reserved]\n\n(4)  Swine.  (i) Liver (target tissue): 3.2 ppm fenbendazole (marker residue).\n\n(ii) [Reserved]\n\n(5)  Turkeys.  (i) Liver (target tissue): 6 ppm fenbendazole sulfone (marker residue).\n\n(ii) [Reserved]\n\n(6)  Quail.  (i) Liver (target tissue): 6 ppm fenbendazole sulfone (marker residue).\n\n(ii) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.905a, 520.905b, 520.905c, 520.905d, and 558.258 of this chapter."], ["21:21:6.0.1.1.18.2.2.37", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.277 Fenprostalene.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of fenprostalene is 0.08 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for fenprostalene are:\n\n(1)  Cattle.  Edible tissues (excluding milk): Not required.\n\n(2)  Swine.  Edible tissues: Not required.\n\n(c)  Related conditions of use.  See \u00a7 522.914 of this chapter."], ["21:21:6.0.1.1.18.2.2.38", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.280 Fenthion.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerance for fenthion is:\n\n(1)  Cattle.  Edible tissues (excluding milk): 0.1 ppm.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 524.920 of this chapter."], ["21:21:6.0.1.1.18.2.2.39", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.283 Florfenicol.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of florfenicol is 10 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for florfenicol amine (marker residue) are:\n\n(1)  Cattle.  (i) Liver (target tissue): 3.7 ppm.\n\n(ii) Muscle: 0.3 ppm.\n\n(2)  Swine.  (i) Liver (target tissue): 2.5 ppm.\n\n(ii) Muscle: 0.2 ppm.\n\n(3)  Catfish.  Muscle (target tissue): 1 ppm.\n\n(4)  Freshwater-reared warmwater finfish (other than catfish) and salmonids.  Muscle/skin (target tissue): 1 ppm.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.955, 522.955, 522.956, and 558.261 of this chapter."], ["21:21:6.0.1.1.18.2.2.4", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.40 Ampicillin.", "FDA", "", "", "[84 FR 32993, July 11, 2019, as amended at 85 FR 18120, Apr. 1, 2020]", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerances for ampicillin are:\n\n(1)  Cattle.  Edible tissues: 0.01 ppm.\n\n(2)  Swine.  Edible tissues: 0.01 ppm.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.90c, 522.90a, and 522.90b of this chapter."], ["21:21:6.0.1.1.18.2.2.40", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.286 Flunixin.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of flunixin is 0.72 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for flunixin are:\n\n(1)  Cattle.  (i) Liver (target tissue): 125 ppb flunixin free acid (marker residue).\n\n(ii) Muscle: 25 ppb flunixin free acid.\n\n(iii) Milk: 2 ppb 5-hydroxy flunixin (marker residue).\n\n(2)  Swine.  (i) Liver (target tissue): 30 ppb flunixin free acid (marker residue).\n\n(ii) Muscle: 25 ppb flunixin free acid.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 522.956, 522.970, 522.1664, and 524.970 of this chapter."], ["21:21:6.0.1.1.18.2.2.41", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.290 Fluralaner.", "FDA", "", "", "[91 FR 5301, Feb. 6, 2026]", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of fluralaner is 10 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for parent fluralaner (marker residue) are:\n\n(1)  Chickens.  (i) Liver (target tissue): 320 ppb.\n\n(ii) Muscle: 110 ppb.\n\n(iii) Eggs: 2500 ppb.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 520.999 of this chapter."], ["21:21:6.0.1.1.18.2.2.42", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.292 Gamithromycin.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of gamithromycin is 10 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for gamithromycin (marker residue) are:\n\n(1)  Cattle.  (i) Liver (target tissue): 500 ppb.\n\n(ii) Muscle: 150 ppb.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 522.1014 of this chapter."], ["21:21:6.0.1.1.18.2.2.43", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.300 Gentamicin.", "FDA", "", "", "[84 FR 32993, July 11, 2019, as amended at 86 FR 13188, Mar. 8, 2021]", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of gentamicin is 60 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for gentamicin are:\n\n(1)  Chickens and turkeys.  Edible tissues (excluding eggs): 0.1 ppm.\n\n(2)  Swine.  (i) Liver: 0.3 ppm.\n\n(ii) Kidney (target tissue): 0.4 ppm gentamicin (marker residue).\n\n(iii) Fat: 0.4 ppm.\n\n(iv) Muscle: 0.1 ppm.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.1044a, 520.1044b, 520.1044c, 522.1044, 524.1044e, and 529.1044b of this chapter."], ["21:21:6.0.1.1.18.2.2.44", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.304 Gonadotropin.", "FDA", "", "", "[84 FR 32993, July 11, 2019, as amended at 85 FR 18121, Apr. 1, 2020]", "(a)  Acceptable daily intake (ADI).  The ADI for residues of total gonadotropins (human chorionic gonadotropin and pregnant mare serum gonadotropin) is 42.25 International Units per kilogram of body weight per day.\n\n(b)  Tolerances.  The tolerances for gonadotropin are:\n\n(1)  Cattle.  Edible tissues (excluding milk): Not required.\n\n(2)  Fish.  Edible tissues: Not required.\n\n(3)  Swine.  Edible tissues: Not required.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 522.1079 and 522.1081 of this chapter."], ["21:21:6.0.1.1.18.2.2.45", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.308 Halofuginone.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of halofuginone hydrobromide is 0.7 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for halofuginone (marker residue) are:\n\n(1)  Chickens.  Liver (target tissue): 0.16 ppm.\n\n(2)  Turkeys.  Liver (target tissue): 0.13 ppm.\n\n(c)  Related conditions of use.  See \u00a7 558.265 of this chapter."], ["21:21:6.0.1.1.18.2.2.46", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.310 Haloxon.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerance for haloxon is:\n\n(1)  Cattle.  Edible tissues (excluding milk): 0.1 ppm.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.1120a and 520.1120b of this chapter."], ["21:21:6.0.1.1.18.2.2.47", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.316 Hetacillin.", "FDA", "", "", "[84 FR 53311, Oct. 7, 2019]", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerances for ampicillin (marker residue for hetacillin) are:\n\n(1)  Cattle. Edible tissues:  0.01 ppm.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 526.1130 of this chapter."], ["21:21:6.0.1.1.18.2.2.48", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.330 Hygromycin B.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerances for hygromycin B are:\n\n(1)  Chickens.  Edible tissues: Zero.\n\n(2)  Swine.  Edible tissues: Zero.\n\n(c)  Related conditions of use.  See \u00a7 558.274 of this chapter."], ["21:21:6.0.1.1.18.2.2.49", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.344 Ivermectin.", "FDA", "", "", "[84 FR 32993, July 11, 2019, as amended at 85 FR 18121, Apr. 1, 2020]", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of ivermectin is 5 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for 22,23-dihydroavermectin B 1 a (marker residue) are:\n\n(1)  American bison.  Liver (target tissue): 15 ppb.\n\n(2)  Cattle.  (i) Liver (target tissue): 1.6 ppm.\n\n(ii) Muscle: 650 ppb.\n\n(3)  Reindeer.  Liver (target tissue): 15 ppb.\n\n(4)  Sheep.  Liver (target tissue): 30 ppb.\n\n(5)  Swine.  (i) Liver (target tissue): 20 ppb.\n\n(ii) Muscle: 20 ppb.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.1192, 520.1195, 520.1197, 522.1192, 522.1193, 524.1193, and 558.300 of this chapter."], ["21:21:6.0.1.1.18.2.2.5", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.50 Amprolium.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerances for amprolium are:\n\n(1)  Cattle.  (i) Liver, kidney, and muscle: 0.5 ppm.\n\n(ii) Fat: 2.0 ppm.\n\n(2)  Chickens and turkeys.  (i) Liver and kidney: 1 ppm.\n\n(ii) Muscle: 0.5 ppm.\n\n(iii) Eggs:\n\n(A) Egg yolks: 8 ppm.\n\n(B) Whole eggs: 4 ppm.\n\n(3)  Pheasants.  (i) Liver: 1 ppm.\n\n(ii) Muscle: 0.5 ppm.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.100, 558.55, and 558.58 of this chapter."], ["21:21:6.0.1.1.18.2.2.50", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.345 Ketoprofen.", "FDA", "", "", "[86 FR 61686, Nov. 8, 2021]", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of ketoprofen is 5 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for ketoprofen (marker residue) are:\n\n(1)  Cattle.  (i) Kidney (target tissue): 0.36 ppm.\n\n(ii) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7\u00a7 522.1225 and 522.2632 of this chapter."], ["21:21:6.0.1.1.18.2.2.51", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.346 Laidlomycin.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of laidlomycin is 7.5 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerance for laidlomycin (marker residue) is:\n\n(1)  Cattle.  Liver (target tissue): 0.2 ppm.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 558.305 of this chapter."], ["21:21:6.0.1.1.18.2.2.52", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.347 Lasalocid.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of lasalocid is 10 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for lasalocid (marker residue) are:\n\n(1)  Cattle.  Liver (target tissue): 0.7 ppm.\n\n(2)  Chickens.  (i) Skin with adhering fat (target tissue): 1.2 ppm.\n\n(ii) Liver: 0.4 ppm.\n\n(3)  Rabbits.  Liver (target tissue): 0.7 ppm.\n\n(4)  Sheep.  Liver (target tissue): 1.0 ppm.\n\n(5)  Turkeys.  (i) Liver (target tissue): 0.4 ppm.\n\n(ii) Skin with adhering fat: 0.4 ppm.\n\n(c)  Related conditions of use.  See \u00a7 558.311 of this chapter."], ["21:21:6.0.1.1.18.2.2.53", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.350 Levamisole.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerances for levamisole are:\n\n(1)  Cattle.  Edible tissues (excluding milk): 0.1 ppm.\n\n(2)  Sheep.  Edible tissues (excluding milk): 0.1 ppm.\n\n(3)  Swine.  Edible tissues: 0.1 ppm.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.1242a, 520.1242b, 520.1242d, 520.1242e, 520.1242f, 520.1242g, 522.1242, and 524.1240 of this chapter."], ["21:21:6.0.1.1.18.2.2.54", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.360 Lincomycin.", "FDA", "", "", "[84 FR 32993, July 11, 2019, as amended at 85 FR 18121, Apr. 1, 2020]", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of lincomycin is 25 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for lincomycin are:\n\n(1)  Chickens.  Edible tissues (excluding eggs): Not required.\n\n(2)  Swine.  (i) Liver: 0.6 ppm.\n\n(ii) Muscle: 0.1 ppm.\n\n(3)  Honey.  750 ppb.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.1263b, 522.1260, and 558.325 of this chapter."], ["21:21:6.0.1.1.18.2.2.55", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.370 Lubabegron.", "FDA", "", "", "[84 FR 12494, Apr. 2, 2019, as amended at 87 FR 17947, Mar. 29, 2022]", "(a)  Acceptable daily intake (ADI).  The ADI for total residues of lubabegron is 3 micrograms per kilogram of body weight per day.\n\n(b)  Tolerances.  The tolerances for lubabegron (marker residue) are:\n\n(1)  Cattle.  (i) Liver (target tissue): 10 ppb.\n\n(ii) Muscle: 3 ppb.\n\n(iii) Kidney: 20 ppb.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 558.330 of this chapter."], ["21:21:6.0.1.1.18.2.2.56", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.375 Maduramicin.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerance for maduramicin (marker residue) is:\n\n(1)  Chickens.  Fat (target tissue): 0.38 ppm.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 558.340 of this chapter."], ["21:21:6.0.1.1.18.2.2.57", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.380 Melengestrol.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerance for melengestrol is:\n\n(1)  Cattle.  Fat: 25 ppb.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 558.342 of this chapter."], ["21:21:6.0.1.1.18.2.2.58", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.410 Metoserpate.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerance for metoserpate is:\n\n(1)  Chickens.  Edible tissues (excluding eggs): 0.02 ppm.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 520.1422 of this chapter."], ["21:21:6.0.1.1.18.2.2.59", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.420 Monensin.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of monensin is 12.5 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for monensin are:\n\n(1)  Cattle.  (i) Liver: 0.10 ppm.\n\n(ii) Muscle, kidney, and fat: 0.05 ppm.\n\n(iii) Milk: Not required.\n\n(2)  Chickens and turkeys.  Edible tissues (excluding eggs): Not required.\n\n(3)  Goats.  Edible tissues (excluding milk): 0.05 ppm.\n\n(4)  Quail.  Edible tissues (excluding eggs): Not required.\n\n(c)  Related conditions of use.  See \u00a7 558.355 of this chapter."], ["21:21:6.0.1.1.18.2.2.6", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.52 Apramycin.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of apramycin is 25 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerance for apramycin (marker residue) is:\n\n(1)  Swine.  Kidney (target tissue): 0.1 ppm.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.110 and 558.59 of this chapter."], ["21:21:6.0.1.1.18.2.2.60", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.425 Morantel.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of morantel tartrate is 10 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for N-methyl-1,3-propanediamine (marker residue) are:\n\n(1)  Cattle.  (i) Liver (target tissue): 0.7 ppm.\n\n(ii) Milk: Not required.\n\n(2)  Goats.  (i) Liver (target tissue): 0.7 ppm.\n\n(ii) Milk: Not required.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.1450a, 520.1450b, 520.1450c, and 558.360 of this chapter."], ["21:21:6.0.1.1.18.2.2.61", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.426 Moxidectin.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of moxidectin is 4 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for moxidectin (marker residue) are:\n\n(1)  Cattle.  (i) Fat (target tissue): 900 ppb.\n\n(ii) Liver: 200 ppb.\n\n(iii) Muscle: 50 ppb.\n\n(iv) Milk: 40 ppb.\n\n(2)  Sheep.  (i) Fat (target tissue): 900 ppb.\n\n(ii) Liver: 200 ppb.\n\n(iii) Muscle: 50 ppb.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.1454, 522.1450, and 524.1450 of this chapter."], ["21:21:6.0.1.1.18.2.2.62", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.428 Narasin.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of narasin is 5 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerance for narasin (marker residue) is:\n\n(1)  Chickens.  Abdominal fat (target tissue): 480 ppb.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7\u00a7 558.363 and 558.364 of this chapter."], ["21:21:6.0.1.1.18.2.2.63", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.430 Neomycin.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of neomycin is 6 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for neomycin are:\n\n(1)  Cattle.  (i) Kidney (target tissue): 7.2 ppm.\n\n(ii) Liver: 3.6 ppm.\n\n(iii) Muscle: 1.2 ppm.\n\n(iv) Fat: 7.2 ppm.\n\n(v) Milk: 0.15 ppm.\n\n(2)  Sheep and goats.  (i) Kidney (target tissue): 7.2 ppm.\n\n(ii) Liver: 3.6 ppm.\n\n(iii) Muscle: 1.2 ppm.\n\n(iv) Fat: 7.2 ppm.\n\n(v) Milk: 0.15 ppm.\n\n(3)  Swine.  (i) Kidney (target tissue): 7.2 ppm.\n\n(ii) Liver: 3.6 ppm.\n\n(iii) Muscle: 1.2 ppm.\n\n(iv) Fat: 7.2 ppm.\n\n(4)  Turkeys.  (i) Skin with adhering fat: 7.2 ppm.\n\n(ii) Liver: 3.6 ppm.\n\n(iii) Muscle: 1.2 ppm.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.1484, 524.1600b, 558.365, and 558.455 of this chapter."], ["21:21:6.0.1.1.18.2.2.64", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.445 Nicarbazin.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residues of nicarbazin (4,4\u2032-dinitrocarbanilide and 2-hydroxy-4,6-dimethylpyrimidine) is 200 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerance for 4,4\u2032-dinitrocarbanilide (marker residue) is:\n\n(1)  Chickens.  Liver (target tissue): 52 ppm.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7\u00a7 558.364 and 558.366 of this chapter."], ["21:21:6.0.1.1.18.2.2.65", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.460 Novobiocin.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerances for novobiocin are:\n\n(1)  Cattle.  (i) Edible tissues (excluding milk): 1 ppm.\n\n(ii) Milk: 0.1 ppm.\n\n(2)  Chickens, turkeys, and ducks.  Edible tissues (excluding eggs): 1 ppm.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 526.1590, 526.1696d, and 558.415 of this chapter."], ["21:21:6.0.1.1.18.2.2.66", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.470 Nystatin.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerances for nystatin are:\n\n(1)  Cattle.  Edible tissues (excluding milk): Zero.\n\n(2)  Chickens and turkeys.  Edible tissues: Zero.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 524.1600b and 558.430 of this chapter."], ["21:21:6.0.1.1.18.2.2.67", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.490 Ormetoprim.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerances for ormetoprim are:\n\n(1)  Chickens, turkeys, ducks, and chukar partridges.  Edible tissues (excluding eggs): 0.1 ppm.\n\n(2)  Salmonids and catfish.  Edible tissues: 0.1 ppm.\n\n(c)  Related conditions of use.  See \u00a7 558.575 of this chapter."], ["21:21:6.0.1.1.18.2.2.68", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.495 Oxfendazole.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of oxfendazole is 7 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerance for fenbendazole (marker residue) is:\n\n(1)  Cattle.  Liver (target tissue): 0.8 ppm.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.1629 and 520.1630 of this chapter."], ["21:21:6.0.1.1.18.2.2.69", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.500 Oxytetracycline.", "FDA", "", "", "[84 FR 32993, July 11, 2019, as amended at 85 FR 18121, Apr. 1, 2020; 88 FR 16549, Mar. 20, 2023, 88 FR 55567, Aug. 16, 2023]", "(a)  Acceptable daily intake (ADI).  The ADI for total tetracycline residues (chlortetracycline, oxytetracycline, and tetracycline) is 25 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for the sum of tetracycline residues are:\n\n(1)  Cattle.  (i) Muscle: 2 ppm.\n\n(ii) Liver: 6 ppm.\n\n(iii) Fat and kidney: 12 ppm.\n\n(iv) Milk: 0.3 ppm.\n\n(2)  Chickens and turkeys.  (i) Muscle: 2 ppm.\n\n(ii) Liver: 6 ppm.\n\n(iii) Fat and kidney: 12 ppm.\n\n(3)  Finfish.  Muscle (with adhering skin when edible): 2 ppm.\n\n(4)  Lobster.  Muscle: 2 ppm.\n\n(5)  Swine and sheep.  (i) Muscle: 2 ppm.\n\n(ii) Liver: 6 ppm.\n\n(iii) Fat and kidney: 12 ppm.\n\n(6)  Honey.  750 ppb.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.1660c, 520.1660d, 520.1664, 522.1660a, 522.1660b, 522.1662, 522.1664, 529.1660, 558.450, and 558.455 of this chapter."], ["21:21:6.0.1.1.18.2.2.7", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.60 Avilamycin.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of avilamycin is 1.1 mg/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for avilamycin are:\n\n(1)  Chickens.  Edible tissues (excluding eggs): Not required.\n\n(2)  Swine.  Edible tissues: Not required.\n\n(c)  Related conditions of use.  See \u00a7 558.68 of this chapter."], ["21:21:6.0.1.1.18.2.2.70", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.510 Penicillin.", "FDA", "", "", "[84 FR 32993, July 11, 2019, as amended at 85 FR 18121, Apr. 1, 2020; 86 FR 13188, Mar. 8, 2021]", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerances for penicillin are:\n\n(1)  Cattle.  (i) Edible tissues (excluding milk): 0.05 ppm.\n\n(ii) Milk: Zero.\n\n(2)  Chickens.  Edible tissues: Zero.\n\n(3)  Pheasants and quail.  Edible tissues: Zero.\n\n(4)  Sheep and swine.  Edible tissues: Zero.\n\n(5)  Turkeys.  Edible tissues (excluding eggs): 0.01 ppm.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.1696a, 522.1696a, 522.1696b, 526.1696, 526.1697, and 526.1698 of this chapter."], ["21:21:6.0.1.1.18.2.2.71", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.515 Pirlimycin.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of pirlimycin is 0.01 mg/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for pirlimycin (marker residue) are:\n\n(1)  Cattle.  (i) Liver (target tissue): 0.5 ppm.\n\n(ii) Muscle: 0.3 ppm.\n\n(iii) Milk: 0.4 ppm.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 526.1810 of this chapter."], ["21:21:6.0.1.1.18.2.2.72", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.517 Poloxalene.", "FDA", "", "", "[84 FR 32993, July 11, 2019, as amended at 86 FR 14821, Mar. 19, 2021]", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerance for poloxalene is:\n\n(1)  Cattle.  Edible tissues (excluding milk): Not required.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.1840 and 558.464 of this chapter."], ["21:21:6.0.1.1.18.2.2.73", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.530 Pradofloxacin.", "FDA", "", "", "[89 FR 85428, Oct. 28, 2024]", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of pradofloxacin is 2 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for pradofloxacin (marker residue) are:\n\n(1)  Cattle.  Kidney (target tissue): 30 ppb.\n\n(2)  Swine.  Kidney (target tissue): 1 ppm.\n\n(c)  Related conditions of use.  See \u00a7 522.1860 of this chapter."], ["21:21:6.0.1.1.18.2.2.74", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.540 Progesterone.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Residues.  Residues of progesterone are not permitted in excess of the following increments above the concentrations of progesterone naturally present in untreated animals:\n\n(1)  Cattle and sheep.  (i) Muscle: 5 ppb.\n\n(ii) Liver: 15 ppb.\n\n(iii) Kidney: 30 ppb.\n\n(iv) Fat: 30 ppb.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7\u00a7 522.1940 and 529.1940 of this chapter."], ["21:21:6.0.1.1.18.2.2.75", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.560 Pyrantel.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerances for pyrantel are:\n\n(1)  Swine.  (i) Liver and kidney: 10 ppm.\n\n(ii) Muscle: 1 ppm.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.2045 and 558.485 of this chapter."], ["21:21:6.0.1.1.18.2.2.76", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.570 Ractopamine.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of ractopamine hydrochloride is 1.25 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for ractopamine (marker residue) are:\n\n(1)  Cattle.  (i) Liver (target tissue): 0.09 ppm.\n\n(ii) Muscle: 0.03 ppm.\n\n(2)  Swine.  (i) Liver (target tissue): 0.15 ppm.\n\n(ii) Muscle: 0.05 ppm.\n\n(3)  Turkeys.  (i) Liver (target tissue): 0.45 ppm.\n\n(ii) Muscle: 0.1 ppm.\n\n(c)  Related conditions of use.  See \u00a7 558.500 of this chapter."], ["21:21:6.0.1.1.18.2.2.77", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.580 Robenidine.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerances for robenidine are:\n\n(1)  Chickens.  (i) Skin and fat: 0.2 ppm.\n\n(ii) Other edible tissues (excluding eggs): 0.1 ppm.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 558.515 of this chapter."], ["21:21:6.0.1.1.18.2.2.78", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.592 Salinomycin.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of salinomycin is 5 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for salinomycin are:\n\n(1)  Chickens.  Edible tissues (excluding eggs): Not required.\n\n(2)  Quail.  Edible tissues (excluding eggs): Not required.\n\n(c)  Related conditions of use.  See \u00a7 558.550 of this chapter."], ["21:21:6.0.1.1.18.2.2.79", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.597 Semduramicin.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of semduramicin is 3 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for semduramicin are:\n\n(1)  Chickens.  (i) Liver: 400 ppb.\n\n(ii) Muscle: 130 ppb.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 558.555 of this chapter."], ["21:21:6.0.1.1.18.2.2.8", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.68 Azaperone.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of azaperone is 0.63 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerance for azaperone is:\n\n(1)  Swine.  Edible tissues: Not required.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 522.150 of this chapter."], ["21:21:6.0.1.1.18.2.2.80", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.600 Spectinomycin.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of spectinomycin is 25 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for spectinomycin are:\n\n(1)  Cattle.  (i) Kidney (target tissue): 4 ppm spectinomycin (marker residue).\n\n(ii) Muscle: 0.25 ppm.\n\n(2)  Chickens and turkeys.  Edible tissues (excluding eggs): 0.1 ppm.\n\n(3)  Swine.  Edible tissues: Not required.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.1265, 520.2123b, 520.2123c, 522.2120, and 522.2121 of this chapter."], ["21:21:6.0.1.1.18.2.2.81", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.610 Streptomycin.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerances for streptomycin are:\n\n(1)  Cattle and swine.  (i) Kidney: 2.0 ppm.\n\n(ii) Other edible tissues (excluding milk): 0.5 ppm.\n\n(2)  Chickens.  (i) Kidney: 2.0 ppm.\n\n(ii) Other edible tissues (excluding eggs): 0.5 ppm.\n\n(c)  Related conditions of use.  See \u00a7 520.2158 of this chapter."], ["21:21:6.0.1.1.18.2.2.82", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.625 Sulfachloropyrazine.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerance for sulfachloropyrazine is:\n\n(1)  Chickens.  Edible tissues (excluding eggs): Zero.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 520.2184 of this chapter."], ["21:21:6.0.1.1.18.2.2.83", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.630 Sulfachlorpyridazine.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerances for sulfachlorpyridazine are:\n\n(1)  Cattle and swine.  Edible tissues (excluding milk): 0.1 ppm.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.2200 and 522.2200 of this chapter."], ["21:21:6.0.1.1.18.2.2.84", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.640 Sulfadimethoxine.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerances for sulfadimethoxine are:\n\n(1)  Catfish and salmonids.  Edible tissues: 0.1 ppm.\n\n(2)  Cattle.  (i) Edible tissues (excluding milk): 0.1 ppm.\n\n(ii) Milk: 0.01 ppm.\n\n(3)  Chickens, turkeys, ducks, and chukar partridges.  Edible tissues (excluding eggs): 0.1 ppm.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.2220a, 520.2220d, 520.2220e, 522.2220, and 558.575 of this chapter."], ["21:21:6.0.1.1.18.2.2.85", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.650 Sulfaethoxypyridazine.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerances for sulfaethoxypyridazine are:\n\n(1)  Cattle.  (i) Edible tissues (excluding milk): 0.1 ppm.\n\n(ii) Milk: Zero.\n\n(2)  Swine.  Edible tissues: Zero.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.2240a, 520.2240b, and 522.2240 of this chapter."], ["21:21:6.0.1.1.18.2.2.86", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.660 Sulfamerazine.", "FDA", "", "", "[84 FR 32993, July 11, 2019, as amended at 85 FR 18121, Apr. 1, 2020]", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerance for sulfamerazine is:\n\n(1)  Trout.  Edible tissues: Zero.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.2218 and 558.582 of this chapter."], ["21:21:6.0.1.1.18.2.2.87", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.670 Sulfamethazine.", "FDA", "", "", "[84 FR 32993, July 11, 2019, as amended at 85 FR 18121, Apr. 1, 2020; 86 FR 13188, Mar. 8, 2021]", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerances for sulfamethazine are:\n\n(1)  Cattle.  Edible tissues (excluding milk): 0.1 ppm.\n\n(2)  Chickens and turkeys.  Edible tissues (excluding eggs): 0.1 ppm.\n\n(3)  Swine.  Edible tissues: 0.1 ppm.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.445, 520.2218, 520.2260a, 520.2260b, 520.2260c, 520.2261a, 520.2261b, 522.2260, 558.140, and 558.630 of this chapter."], ["21:21:6.0.1.1.18.2.2.88", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.685 Sulfaquinoxaline.", "FDA", "", "", "[84 FR 32993, July 11, 2019, as amended at 85 FR 18121, Apr. 1, 2020]", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerances for sulfaquinoxaline are:\n\n(1)  Cattle.  Edible tissues (excluding milk): 0.1 ppm.\n\n(2)  Chickens and turkeys.  Edible tissues (excluding eggs): 0.1 ppm.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.2218, 520.2325a, 520.2325b, and 558.586 of this chapter."], ["21:21:6.0.1.1.18.2.2.89", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.700 Sulfomyxin.", "FDA", "", "", "", "(a) [Reserved]\n\n(b)  Tolerances.  The tolerances for sulfomyxin are:\n\n(1)  Chickens and turkeys.  Edible tissues (excluding eggs): Zero.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 522.2340 of this chapter."], ["21:21:6.0.1.1.18.2.2.9", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.70 Bacitracin.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of bacitracin is 0.05 mg/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for bacitracin are:\n\n(1)  Cattle.  Edible tissues: 0.5 ppm.\n\n(2)  Chickens, turkeys, pheasants, quail.  Edible tissues: 0.5 ppm.\n\n(3)  Swine.  Edible tissues: 0.5 ppm.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.154a, 520.154c, 558.76, and 558.78 of this chapter."], ["21:21:6.0.1.1.18.2.2.90", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.710 Testosterone.", "FDA", "", "", "[84 FR 32993, July 11, 2019, as amended at 87 FR 10970, Feb. 28, 2022]", "(a) [Reserved]\n\n(b)  Residues.  Residues of testosterone are not permitted in excess of the following increments above the concentrations of testosterone naturally present in untreated animals:\n\n(1)  Cattle.  (i) Fat: 2.6 ppb.\n\n(ii) Kidney: 1.9 ppb.\n\n(iii) Liver: 1.3 ppb.\n\n(iv) Muscle: 0.64 ppb.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 522.2343 of this chapter."], ["21:21:6.0.1.1.18.2.2.91", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.720 Tetracycline.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total tetracycline residues (chlortetracycline, oxytetracycline, and tetracycline) is 25 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerances for the sum of tetracycline residues are:\n\n(1)  Cattle and sheep.  (i) Kidney and fat: 12 ppm.\n\n(ii) Liver: 6 ppm.\n\n(iii) Muscle: 2 ppm.\n\n(2)  Chickens and turkeys.  (i) Kidney and fat: 12 ppm.\n\n(ii) Liver: 6 ppm.\n\n(iii) Muscle: 2 ppm.\n\n(3)  Swine.  (i) Kidney and fat: 12 ppm.\n\n(ii) Liver: 6 ppm.\n\n(iii) Muscle: 2 ppm.\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.2345c and 520.2345d of this chapter."], ["21:21:6.0.1.1.18.2.2.92", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.732 Tiamulin.", "FDA", "", "", "", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of tiamulin is 25 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerance for 8-alpha-hydroxymutilin (marker residue) is:\n\n(1)  Swine.  Liver (target tissue): 0.6 ppm.\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7\u00a7 520.2455 and 558.612 of this chapter."], ["21:21:6.0.1.1.18.2.2.93", 21, "Food and Drugs", "I", "E", "556", "PART 556\u2014TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD", "B", "Subpart B\u2014Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs", "", "\u00a7 556.733 Tildipirosin.", "FDA", "", "", "[84 FR 32993, July 11, 2019, as amended at 85 FR 18121, Apr. 1, 2020]", "(a)  Acceptable daily intake (ADI).  The ADI for total residue of tildipirosin is 50 \u00b5g/kg of body weight per day.\n\n(b)  Tolerances.  The tolerance for tildipirosin (the marker residue) is:\n\n(1)  Cattle.  (i) Liver (the target tissue): 10 ppm.\n\n(ii) [Reserved]\n\n(2) [Reserved]\n\n(c)  Related conditions of use.  See \u00a7 522.2460 of this chapter."]], "truncated": false, "filtered_table_rows_count": 115, "expanded_columns": [], "expandable_columns": [], "columns": ["section_id", "title_number", "title_name", "chapter", "subchapter", "part_number", "part_name", "subpart", "subpart_name", "section_number", "section_heading", "agency", "authority", "source_citation", "amendment_citations", "full_text"], "primary_keys": ["section_id"], "units": {}, "query": {"sql": "select section_id, title_number, title_name, chapter, subchapter, part_number, part_name, subpart, subpart_name, section_number, section_heading, agency, authority, source_citation, amendment_citations, full_text from cfr_sections where \"part_number\" = :p0 order by section_id limit 101", "params": {"p0": "556"}}, "facet_results": {"title_number": {"name": "title_number", "type": "column", "hideable": false, "toggle_url": "/openregs/cfr_sections.json?part_number=556", "results": [{"value": 21, "label": 21, "count": 106, "toggle_url": "https://www.pawtectors.org/openregs/cfr_sections.json?part_number=556&title_number=21", "selected": false}, {"value": 49, "label": 49, "count": 9, "toggle_url": "https://www.pawtectors.org/openregs/cfr_sections.json?part_number=556&title_number=49", "selected": false}], "truncated": false}, "agency": {"name": "agency", "type": "column", "hideable": false, "toggle_url": "/openregs/cfr_sections.json?part_number=556", "results": [{"value": "FDA", "label": "FDA", "count": 106, "toggle_url": "https://www.pawtectors.org/openregs/cfr_sections.json?part_number=556&agency=FDA", "selected": false}, {"value": "NHTSA", "label": "NHTSA", "count": 9, "toggle_url": "https://www.pawtectors.org/openregs/cfr_sections.json?part_number=556&agency=NHTSA", "selected": false}], "truncated": false}, "part_number": {"name": "part_number", "type": "column", "hideable": false, "toggle_url": "/openregs/cfr_sections.json?part_number=556", "results": [{"value": "556", "label": "556", "count": 115, "toggle_url": "https://www.pawtectors.org/openregs/cfr_sections.json", "selected": true}], "truncated": false}}, "suggested_facets": [{"name": "title_name", "toggle_url": "https://www.pawtectors.org/openregs/cfr_sections.json?part_number=556&_facet=title_name"}, {"name": "chapter", "toggle_url": "https://www.pawtectors.org/openregs/cfr_sections.json?part_number=556&_facet=chapter"}, {"name": "subchapter", "toggle_url": "https://www.pawtectors.org/openregs/cfr_sections.json?part_number=556&_facet=subchapter"}, {"name": "part_name", "toggle_url": "https://www.pawtectors.org/openregs/cfr_sections.json?part_number=556&_facet=part_name"}, {"name": "subpart", "toggle_url": "https://www.pawtectors.org/openregs/cfr_sections.json?part_number=556&_facet=subpart"}, {"name": "subpart_name", "toggle_url": "https://www.pawtectors.org/openregs/cfr_sections.json?part_number=556&_facet=subpart_name"}, {"name": "amendment_citations", "toggle_url": "https://www.pawtectors.org/openregs/cfr_sections.json?part_number=556&_facet=amendment_citations"}], "next": "21~3A21~3A6~2E0~2E1~2E1~2E18~2E2~2E2~2E93,21~3A21~3A6~2E0~2E1~2E1~2E18~2E2~2E2~2E93", "next_url": "https://www.pawtectors.org/openregs/cfr_sections.json?part_number=556&_next=21~3A21~3A6~2E0~2E1~2E1~2E18~2E2~2E2~2E93%2C21~3A21~3A6~2E0~2E1~2E1~2E18~2E2~2E2~2E93&_sort=section_id", "private": false, "allow_execute_sql": true, "query_ms": 2704.46239807643, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}